Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) is out with news that the preliminary results of the pain score portion of the expansion phase of Ampion in Knee trial which was recently completed in Australia. This company discovers and develops new uses for previously approved drugs and new molecular entities.
Preliminary analysis of the pain scores demonstrated positive results and that means that Ampion™ may be a therapeutic alternative to steroids for osteoarthritis with a very favorable safety profile.
- The overall difference in pain score was 41% at 30 days post injection (compared to baseline <predose baseline 4.45/0.96 mean/SD, versus 2.47/1.9 mean/SD at 30 days, p=0.016>).
- The placebo showed a difference of 28% over the same time period and was not statistically significant.
- With Ampion™, 64% of patients had a clinically meaningful improvement (2 or more on the 1-10 pain scale) and 18% did not benefit.
The company said that reaching any statistically significant effect on a pain score scale with less than 40 patients “is fantastic” and it also noted that some of these changes are greater than what was published in the medical literature for some approved drugs for this condition.
The news looks good on the surface, but we have to wait for trading to begin in these small biotech and emerging pharma players for the final votes of confidence. Ampio shares closed at $4.08 on Monday and the 52-week range is $2.57 to $9.27 and its market capitalization rate is $117.5 million.
Top Gaining Stocks
Top Losing Stocks